2023 World Conference on Lung Cancer (Posters)-P2.17. Recent Patterns across Therapy Lines and Real-World Survival Post First Line PD-L1 Treatment for Small Cell Lung Cancer

P2.17. Recent Patterns across Therapy Lines and Real-World Survival Post First Line PD-L1 Treatment for Small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

A recent study analyzed the treatment patterns and overall survival outcomes of patients with small cell lung cancer (SCLC). The study focused on extensive stage SCLC, which is the most common form of the disease. The use of anti-PD-L1 therapies in the first-line treatment of extensive stage SCLC has significantly increased since 2018 and now constitutes the majority of first-line regimens. Maintenance therapy with atezolizumab or durvalumab was also common among patients receiving first-line anti-PD-L1-based regimens. In terms of second-line treatment, topotecan was commonly used but declined over time, while lurbinectedin became the most used therapy in 2021. No approved therapies exist for third-line treatment, but lurbinectedin and topotecan were the most commonly used treatments in 2021. The study found that the median real-world overall survival after first-line therapy was 8.3 months with anti-PD-L1 therapy and 8.0 months without. The survival rate at 12 months was higher for patients receiving first-line anti-PD-L1 therapy compared to those without. Despite changes in treatment patterns, survival outcomes for SCLC patients remain suboptimal, indicating a need for the development of new approaches to improve survival in this population.

Asset Subtitle

Hossein Borghaei

Meta Tag

Speaker Hossein Borghaei

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

small cell lung cancer

extensive stage SCLC

anti-PD-L1 therapies

first-line treatment

maintenance therapy

atezolizumab

durvalumab

second-line treatment

topotecan

lurbinectedin